Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072768 · ClinicalTrials.gov registry record · Phase 2
Dynamic Treatment Regiments for Glucocorticoid Tapering
A Phase 2 study of Rheumatoid Arthritis, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT06072768: Recruiting Phase 2 study of Rheumatoid Arthritis, sponsored by VA Office of Research and Development.
NCT06072768 is a Phase 2 study of Rheumatoid Arthritis that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 200 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06072768, a Phase 2 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't. This trial will look at different patient characteristics, including levels of inflammation in the body, differences in the way the brain processes sensory information, and certain hormone levels, to help researchers better understand why different people have these different responses to steroid tapering. The hypotheses include: * Greater or equal to ( ) 30% of participants in each arm will develop taper intolerance (either subjective, objective, or both) during the study period * Greater or equal to 60% of participants will reduce Glucocorticoid dose by at least 5 Milligrams per day during the study period
Primary Outcome
Subjective intolerance, the first point when a participant replies elects to stop glucocorticoid taper due to associated symptoms. This will be assessed using a one-question questionnaire with binary "yes" and "no" responses.
Conditions Studied
Interventions
- DRUG 15-day taper prednisone
- DRUG 150-day taper prednisone
Study Locations (2)
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2030-03-01 |
| Phase | Phase 2 |
What NCT06072768 shows while recruiting
NCT06072768 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which 15-day taper prednisone is the first listed.
NCT06072768 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06072768 about?
NCT06072768 is a clinical study titled "Dynamic Treatment Regiments for Glucocorticoid Tapering". The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't. This trial will look at d...
What is the current status of trial NCT06072768?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2023-03-09. Estimated completion is 2030-03-01.
What conditions does trial NCT06072768 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06072768?
The interventions under investigation include: 15-day taper prednisone (DRUG), 150-day taper prednisone (DRUG).
Who is sponsoring clinical trial NCT06072768?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072768 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06072768's enrollment target sits among peer trials
200 84th of 197 higher than 110 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI